Search results for " biopharma"
Article
Biopharma Seeks Balance
Peters
A biopharma company answers to multiple masters: the patient who depends on effective drug products for health or survival; regulatory authorities that monitor quality; …
Article
Digitalization: The Route to Biopharma 4.0
The biopharma industry is still in transition from manual to automated operations, thereby offering an opportunity to incorporate Industry 4.0. Early efforts indicate that multiple challenges are enco…
Article
Challenges and Trends in Biopharma Facility Design
26-30
Facility design is an important aspect of biopharmaceutical manufacturing. “Global deployment, cost pressure, time to market, and change/uncertainty” are some of the factors biopharma comp…
Article
Biopharma Advances Demand Specialized Expertise
The approval of the first biosimilar in the United States, as well as continuing consolidation in the biopharma and contract development and manufacturing markets, are just two indicators of the ongoi…
Article
Framing Biopharma Success in 2016
Peters
The US biopharmaceutical industry turned a new page in 2015 when FDA approved Zarxio (filgrastim-sndz), the first biosimilar approved for use in US markets, in March 2015. Biotechnology sto…
Article
Biopharma in 2016: Higher Quality Drugs, Less Expensive Manufacturing
The global biopharmaceuticals market was valued at $162 billion in 2014 and pre¬dicted by Persistence Market Research to grow at a compound annual growth rate of 9.4% from 2014 to 2020 to reach $278 b…
Article
Speed and Flexibility Are Dual Goals for Biopharma Operations
In addition, biopharma companies and contract manufacturers seek the flexibility to produce multiple products on a single line with minimal downtime for cleaning and changeover.
Modular processing…
Article
Biopharma Says It Has an Evolution in New Technologies and Processes
However, most product introductions focused on enhancements to existing product lines or technologies to improve current biopharmaceutical manufacturing processes. A recurring theme was the need for n…
Article
The Affordable Care Act's Impact on Innovation in Biopharma
The Affordable Care Act (ACA) has elicited intense national debate and sent biopharmaceutical companies scrambling to understand how their business model, including its ability to innovate, will chang…
Article
Boosting biopharma resilience: The need to shift focus and increase collaboration
The 2023 Global Biopharma Resilience Index from Cytiva offers insights into the current state of the industry, shining a light on both areas of strength and opportunities for collaborative growth. By …